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INTRODUCTION
The World Health Organization estimates the prevalence of diabetes worldwide across all age groups at 4.4% in year 
2030 – an increase by about 1.6% from the year 2000.1 This 
should amount to an increase from 171 million to about 366 
millions in actual numbers.
Diabetic retinopathy (DR) affects 1 in 3 persons with diabetes 
and is the leading cause of vision loss in adult persons of working 
age. Patients with DR have been reported to have poorer quality 
of life reduced physical, emotional and social wellbeing, and to 
utilize more healthcare resources.2
In the US, among the adults 40 years or older with diabetes 
mellitus, the prevalence of DR has been estimated at 40.3% and 
that of vision‑threatening retinopathy, which includes diabetic 
macular edema (DME), is estimated at 8.2%.3 Globally, it has 
been estimated that up to 100 million people have DR and 
more than 20 million will have vision‑threatening retinopathy.4
The present‑day management of DR revolves around laser 
photocoagulation for proliferative disease; laser photocoagulation, 
intra‑vitreal anti‑vascular endothelial growth factor (VEGF) agents 
and steroids for DME. Vitreo retinal surgery is reserved for the more 
serious complications such as vitreous hemorrhage, traction and 
combined retinal detachment, premacular vitreoretinal traction.5
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While most agree that microvascular changes including DR 
are duration dependent to a great degree, there are obviously 
other factors that influence the onset and progression of the 
retinopathy. In this regard, many ocular treatments are indicated 
only when retinopathy has set in, and is akin to “fire fighting”. 
Laser photocoagulation, for example, remains the first and often 
repeated modality of treatment in most countries; unfortunately 
this modality is destructive in nature and leads to variable loss of 
peripheral field in an attempt to preserve some central vision.
Thus, systemic therapy could be preventive and hence potentially 
could have more impact on the overall public health outcome 
for the society at large.6 Systemic approaches to treatment 
are aimed at preventing retinopathy, delaying the onset of 
retinopathy, reversing retinopathy (in some cases), or delaying 
the progression of early to advanced stages of retinopathy.
In this article we discuss some of the current concepts related 
to systemic therapy in diabetic retinopathy using the evidence 
from various clinical trials [Table 1].
Glycemic control
Considering the fact that diabetes is primarily defined by raised 
blood glucose levels, it makes logical sense that good glycemic 
control should have beneficial effect on secondary effects of 
diabetes including microvascular complications and retinopathy.
The evidence
Two major trials‑ the Diabetes control and complications trial 
(DCCT)7 involving insulin‑dependent diabetics and the United 
Kingdom prospective diabetes study group (UKPDS)8 involving 
non‑insulin‑dependent diabetics have answered the question 
in the affirmative. The DCCT has shown that a 10% reduction 
in HbA1c (e.g., 8‑7.2%) is associated with a 43% reduction 
in progression of retinopathy in the intensive treatment 
group and 45% reduction in progression of retinopathy in the 
conventional treatment group‑ indicating that it is ultimately 
the control of blood glucose that is important. The study also 
showed that both the levels of HbA1c at start of the trial as 
well as the level achieved during the trial influenced the rate of 
progression of retinopathy. However, significantly the intensive 
treatment group had more incidence of hypoglycemic episodes. 
Follow‑up studies on this group of patients have shown that 
the benefit of tight control on the progression of retinopathy 
was maintained, despite reducing difference in the values of 
HbA1c between the groups over time‑ a concept of “metabolic 
memory”.9
The UKPDS8 studied similar tight control versus conventional 
control for type 2 diabetes. After 6 years of follow‑up, the 
intensive treatment group had significantly smaller rate of the 
two‑step progression of diabetic retinopathy (even if need for 
photocoagulation was excluded).
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
trial was designed primarily to study the affect of even more 
intensive glycemic control (than DCCT) on cardiovascular 
and microvascular events in patients with type 2 diabetes. The 
ACCORD eye study group has found a 33% reduction in the 
progression of DR in the intensive control group after a short 
period of 4 years.10
In contrast, the Veterans affairs diabetes study did not show 
any significant difference in the progression of microvascular 
changes after tight control of glycemia. Specifically, the study 
noted that the incidence of new ocular procedures; conversion 
to proliferative disease; and occurrence of macular edema were 
similar in both the groups while a non‑significant beneficial trend 
was noted in terms of two‑step progression of the retinopathy.11
Most reports mention halted or delayed progress of retinopathy 
but not reversal of established retinopathy. Very early retinal 
changes (such as increased fluorescein leak on vitreous 
fluorometry) has been shown to get reversed with intense 
glycemic control.12
An important issue to note is that tight control of blood 
glucose has been reported to cause early worsening of diabetic 
retinopathy and this has been attributed to up regulation 
of insulin‑like growth factor‑1 (IGF‑1).13‑15 There are also 
case reports of rapid progression to florid retinopathy in 
insulin‑dependent young diabetics, when put on intensive 
control of glycemia with continuous subcutaneous insulin 
infusion.16 However, these patients also had significant other 
co‑existing problems such as severe nephropathy. The ACCORD 
trial has shown increased risk of hypoglycemic episodes requiring 
medical assistance in the group with intensive treatment (aiming 
at <6% HbA1c). There was also increased rate of death from 
any cause in the group with intensive treatment ‑5% versus 4% 
in the conventional treatment.10
The inference
From a clinical practice perspective, it is perhaps impossible to 
replicate on a daily basis, the rigorous regimen of blood glucose 
control practiced in DCCT, ACCORD, and other trials. The 
message, however, is clear: better glucose control is associated 
with less risk of progression of DR. Good glycemic control 
right from diagnosis is beneficial in preventing the onset of 
diabetic retinopathy as well as in delaying the progression of 
the retinopathy. A ‘good’ control of glycemia is aimed at but 
not necessarily below normalcy. The long‑term benefits of good 
control of glycemia outweigh the small risk of early worsening 
of retinopathy.
Control of hypertension
Hypertension is very often coexistent with diabetes. In a review 
publication by Mohan et al., the incidence of hypertension 
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among type 2 diabetics was quoted at 20.6% in India, 78.4% 
in Thailand, 9.7% in Nigeria and 70.4% in Morocco.17 Other 
studies have reported a three times greater incidence of 
hypertension among type 2 diabetics compared to age and 
sex‑matched population without diabetes. Considering the 
known vascular damage that occurs with hypertension, there 
is expected to be additive affect of hypertension on the severity 
of diabetic retinopathy.
The evidence
The UKPDS studied the role of tight control of blood pressure 
on various end points – one of which is the retinopathy and 
visual loss.18 There was a 35% reduction in the progression of 
retinopathy by 2 or more steps in the group with tight control 
of blood pressure. At 9 years follow‑up, the group with tight 
control of blood pressure had a 47% reduction in risk of loss 
of 3 or more lines of vision (on ETDRS chart). Control of 
Table 1. Summary of clinical trials related to systemic treatment in diabetic retinopathy
Title Intervention Results
DCCT (Diabetes control and 
complications trial)
Maintaining near normal blood 
glucose (intensive treatment) 
compared to usual control in insulin 
dependent diabetes
43% reduction in risk of progression of retinopathy for 10% reduction 
in HbA1c. (from 8 to 7.2%)
Metabolic memory-benefit of tight control maintained despite losing 
tight control later on
UKPDS (UK prospective 
diabetes study group)
Tight Vs conventional control of blood 
glucose in type 2 diabetes
25% reduction in microvascular end points (mostly due to reduced 
need for photocoagulation)
ACCORD (Action to control 
cardiovascular risk in 
diabetes) and ACCORD eye 
study group
Intensive control of blood 
glucose (more intensive than in DCCT), 
intensive blood pressure control, and 
combination therapy for dyslipidemia 
in type 2 diabetes
Glycemia control-Progression of DR7.3% vs 10.4% in standard 
therapy (33% reduction)
Use of Fenofibrate-6.5% progression of DR vs 10.2% with placebo
Intensive blood pressure control-10.4% progression of DR vs 8.8% 
with standard therapy
VADT (Veteran affairs diabetes 
trial)
Tight control of glycemia with goal of 
absolute reduction of 1.5 percentage 
points in HbA1c
No affect on the progression to Proliferative DR
No affect on progression to DME
Non-significant trend towards benefit in reducing progression of DR 
by two steps
HDS (part of UKPDS) dealing 
with hypertension control
Additional tight control of 
hypertension (150/85 or lower) with 
captopril or atenolol
At 7.5 yrs, 34% reduction in risk of deterioration of DR by two steps
At 9 years follow-up, 47% reduction in risk of reduced vision by 3 or 
more lines on ETDRS
Prospective cohort study from 
Australia (Donaghue et al.)
Follow up study on type 1 
diabetics (median follow up 4 yrs)
Higher systolic and diastolic blood pressures contribute to early DR 
development independent of glycemic control
BP had a continuous rather than threshold affect
10 mm/hg higher systolic BP associated with 3-20% higher risk of DR
10 mm/hg higher diastolic BP associated with 2-30% higher risk of DR
ADVANCE trial (action in 
diabetes and vascular disease: 
Preterax and diamicron MR 
controlled evaluation)
Effect of blood pressure lowering and 
intensive blood glucose control on 
incidence and progression of DR in 
type 2 DM
BP lowering: Incidence and progression of DR lowered-but not to a 
significant degree (P=0.12)
BP lowering: Significant reduction in occurrence of macular edema
Intensive glucose control-had no affect on incidence and progression 
of DR
Borderline reduction in risk of hard exudates and macular edema
EUCLID trial (EURODIAB 
controlled trial of lisinopril in 
Insulin-dependent diabetes 
mellitus)
Use of lisinopril (ACE inhibitor) in 
insulin dependent diabetics
Non-significant reduction in occurrence of DR
Significant reduction in progression of DR
Affect seen in normotensive patients as well
DIRECT (Diabetic retinopathy 
candesartan trials)
Prevent 1-studied incidence of 
DR in type 1 DM
Protect -1-Studied progression 
of DR in type 1 DM
Protect-2-studied progression 
of DR in type 2 DM
Candesartan (angiotensin 
convertase inhibitor) used
Prevent 1-Reduction incidence of DR to just short of significant 
levels (P=0.0508); post hoc analysis showed significant reduction in 
3 step deterioration of DR
Protect-1-No significant affect on DR progression but final vision 
better
Protect-2-Non significant affect on progression of DR; Significantly 
regression of established mild DR
No affect on PDR or DME
RASS Renin angiotensin blockade 
with enalapril (ACE inhibitor) or 
losartan (angiotensin receptor blocker) 
in normotensive type 1 diabetics
Significant reduction in risk of progression of DR by two steps for 
both drugs
The effect remained after adjusting for the mean blood pressure
FIELD study (fenofibrate 
intervention and event 
lowering in diabetes)
Fenofibrate-a PPAR-α agonist and 
lipid lowering agent used in type 2 
diabetics
Requirement for first laser was lowered
Significant reduction in two-step progression of DR
No effect on the incidence of DR
The effect not related to lipid lowering
STENO-2 study Intensive multifactorial target driven 
intervention in high risk type 2 DM 
with microalbuminuria
Factors targeted were the BP, HbA1c, 
LDL cholesterol, triglycerides
About 50% reduction in risk of retinopathy, nephropathy, and 
cardiovascular risk
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hypertension was also shown to have beneficiary affect on other 
end points such as myocardial infarction, stroke, renal failure, 
etc., In a prospective cohort study, Gallego et al. have identified 
systolic and diastolic pressure as predictors for onset of diabetic 
retinopathy in type 1 diabetes.19 The association was found to 
be linear‑ an increase by 10 mm/hg in systolic blood pressure 
was associated with 3‑20% increased risk of retinopathy and 
an increase by 10 mm/hg in diastolic blood pressure increased 
the risk by 2‑30%.
In contrast to glucose control, follow‑up studies on this group 
of patients have shown that the benefit of tight blood pressure 
control on the progression of retinopathy was not maintained 
over time; thus, blood pressure control has to be sustained 
throughout life.20
The Action in Diabetes and Vascular Disease: Preterax and 
Diamicron MR Controlled Evaluation trial (ADVANCE) used 
perindopril‑indapamide combination versus placebo for control 
of blood pressure in addition to glycemic control. The study, 
however, has shown only marginal benefit on the onset or 
progression of retinopathy with the pressure‑lowering drugs.21 
The reduction in occurrence of macular edema was more 
significant.
The role of the renin‑angiotensin system in the pathogenesis of 
DR has been of increasing interest. A local renin‑angiotensin 
system has been identified to be functional in the eye and has 
been found to be upregulated during DR resulting in increased 
VEGF and other growth factors. Hence blockade of this system 
appears to be a logical approach to control the progression of 
retinopathy. Lisinopril, an angiotensin convertase enzyme (ACE) 
inhibitor, has been used in the EURODIAB trial (EUCLID 
Controlled trial of Lisinopril in Insulin‑Dependent Diabetes 
Mellitus) and has been shown to have non‑significant reduction 
in the occurrence of retinopathy (although not a primary end 
point) and significant reduction in progression of retinopathy.22 
This benefit on progression of retinopathy was noted even in 
normotensive patients with type 1 diabetes. This raises the 
possibility of direct effect of this drug on the retinopathy, outside 
of its blood pressure‑lowering affects.
The DIRECT study is a large trial conducted to test the 
efficacy of Candesartan (an angiotensin receptor blocker) on 
diabetic retinopathy. The study had three components. The 
prevent‑1 that studied the role of this drug in preventing 
diabetic retinopathy in type 1 diabetics and Protect‑1 and 
Protect‑2 that studied the effect of the drug in halting the 
progression of diabetic retinopathy in type 1 and type 2 diabetes, 
respectively.23,24 Treatment with Candesartan was able to reduce 
the incidence of retinopathy by 18% (a marginally significant 
achievement P = 0.0508). Progression of retinopathy could 
not be influenced to a significant degree in both type 1 and 
type 2 diabetes. However, regression (reduction by 2 steps) of 
early stage retinopathy was achieved to a significant degree in 
type 2 diabetes. In general, it is believed that the treatment has 
reduced the retinopathy to a less severe variety more often than 
in the placebo group.
Yet another study‑ the Renin Angiotensin System Study (RASS) 
was designed to primarily study the occurrence of diabetic 
nephropathy, with retinopathy as additional end point. The study 
compared ACE inhibitor Enalapril or Angiotensin II receptor 
blocker Losartan with a placebo. Progression of retinopathy 
was significantly less with the both medications compared 
to placebo even when adjusted for blood pressure‑lowering 
affect of the drugs.25 The study has also demonstrated that 
the night ambulatory diastolic blood pressure is associated 
with increasing severity of diabetic retinopathy and this was 
attributed to the dysfunctional autonomic system in diabetics. 
The authors believe that the protective effect of ACE inhibitors 
and Angiotensin II receptor blockers could be due to the affect 
on the night time blood pressure rather than a direct affect on 
the rennin‑angiotensin system in the eye.26
The inference
Control of blood pressure, along with good glycemic control, 
reduces the risk of progression of retinopathy. Furthermore, 
inhibition of the rennin‑angiotensin pathway by an ACE inhibitor 
or angiotensin II receptor blocker seem to have effects beyond 
the impact of blood pressure control.
Control of dyslipidemia
The association between lipids and DR has been less well 
demonstrated compared to the role of hyperglycemia and 
hypertension.27
The evidence
The Wisconsin Epidemiologic Study of Diabetic Retinopathy 
(WESDR) has not shown any association of cholesterol levels 
with the severity of DR but showed significant association with 
severity and occurrence of hard exudates in young diabetics.28 
The ETDRS study found a two‑fold increase in risk of retinal 
hard exudates with increased levels of cholesterol.29 High 
serum triglycerides have also been shown to be associated with 
increased risk of development and progression of retinopathy 
by Hadjadj et al.30 The DCCT has shown significant association 
between occurrence of clinically significant macular edema 
and levels of LDL as well as total cholesterol‑ HDL ratio.31 
Low levels of HDL cholesterol have been known to be a risk 
factor for cardiovascular disease but the ADVANCE study 
did not show similar relationship between low levels of HDL 
cholesterol and retinopathy although there was a relationship 
with nephropathy.32
The statins and the fibrates have been in use clinically to reduce the 
lipid levels. Statins primarily reduce the LDL cholesterol. Gupta 
et al. had a good success with use of atorvastatin in the reduction of 
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diabetic macular edema.33 Reduction in hard exudates was noted 
in as high as 66.6% cases with statins versus only 13.3% in control 
group. In a study by Gordon et al. of six patients, reduction in 
hard exudates was achieved with pravastatin along with reduction 
in total cholesterol and low‑density lipoproteins.34
Peroxisome proliferator‑activated receptors agonists
Peroxisome proliferator‑activated receptors (PPAR) belong to 
a large super family of nuclear receptors.35 These are ligand 
inducible transcription factors and serve as receptors for thyroid 
hormones, steroids, etc., They regulate the genes involved in 
carbohydrate and lipid metabolism and hence affect the insulin 
sensitivity and lipid homeostasis.36 PPAR‑α and γ are specifically 
of importance for this discussion. Drugs such as rosiglitazone, 
pioglitazone belonging to the group of thiazolidendiones are 
agonists of PPAR‑γ and have serum glucose‑lowering ability.37 
The fibrates are agonists of PPAR‑α and have predominantly 
lipid‑lowering function. Drugs such as Muralglitazar have dual 
(α/γ receptor agonists) affect and are expected to be even better 
since they have affect on lipid control as well as improving 
insulin sensitivity.38
PPAR‑γ agonists are also suggested to have anti‑inflammatory 
role since they have been shown to reduce the inflammatory 
markers such as serum C‑reactive protein, IL‑6, plasminogen 
activator‑1, etc.39
Fenofibrates and diabetic retinopathy
Fibrates are PPAR‑ α agonists and have been extensively tested 
for diabetes and retinopathy.40,41 The FIELD study (Fenofibrate 
Intervention and Event Lowering in Diabetes) is essentially 
a cardiovascular trial. However, the effect on reduction of 
myocardial infarction and coronary death was not found to be 
significant. There was beneficial effect on overall cardiovascular 
events. Study of diabetic retinopathy was actually a tertiary 
end‑point, but showed a significant result. The need for first as 
well as repeat laser treatment for proliferative retinopathy and 
macular edema was significantly reduced with use of fenofibrate 
compared to placebo. A sub‑study of 1012 patients who had 
baseline and follow‑up fundus photographs was also carried out. 
This analysis revealed a markedly significant reduction in the 
need for laser photocoagulation, and also showed a significant 
reduction in 2‑step progression of retinopathy. Incidence of 
macular edema showed non‑significant trend toward reduction.
The mechanism by which fibrates achieved this beneficial 
effect on the retinopathy is, however, unclear. While lipid 
lowering is the identified primary action of fibrates, the 
actual levels of lipid lowering achieved in the study was 
not significant over time (although at 4 months there was 
significant reduction). The benefit on diabetic retinopathy 
progression was achieved against the backdrop of use of ACE 
inhibitors in both groups, as well as more use of statins in the 
placebo group over time.42
The ACCORD study also showed beneficial effect of fenofibrates. 
When added to statins, they significantly slowed the progression 
of diabetic retinopathy in type 2 diabetes mellitus.10 Some of the 





inflammation plays a role in the pathogenesis of DR.45 
The vitreous of PDR patients has been demonstrated to 
have elevated levels of proinflammatory cytokines, such as 
Interleukins‑ IL‑1β, IL‑6 and IL‑8; TNF‑α and vascular 
cell adhesion molecule‑1.46‑48 Increased VEGF and IL‑6 
levels were also detected in the aqueous humor of diabetic 
patients with macular edema.49 Reduced concentrations of 
TNF‑α, Interleukin‑6, and interleukin‑1β have been seen 
with fenofibrates.40,50,51
•	 Antioxidant	property:	Fenofibrates	were	shown	to	reduce	
the concentrations of melondialdehyde‑ a lipidperoxide 
formed due to reactive oxygen species.52
Considering the evidence of benefit of fenofibrates in DR, 
Treacy et al. suggest the exploration of intraocular delivery of 
the same along with anti‑VEGF drugs in the management of 
DR. Currently available fenofibrate (oral) is converted to the 
active form by esterases. Hence bioavailability becomes an 
issue if administered intravitreally. A choline salt (ABT‑335) 
has been identified that does not need activation by esterases.53 
Hopefully the future should see the conversion of this possibility 
into reality.
The inference
Control of dyslipidemia, possibly with fenofibrate, reduces the 
risk of progression of retinopathy.54
Multifactoral intervention
Most previous trials targeted only a single risk factor for DR. The 
effect of a multifactorial approach was investigated in the Steno‑2 
study in patients with type 2 diabetes and microalbuminuria.55,56 
The Steno‑2 study encompassed treatment goals similar to 
those recommended in the American Diabetes Association 
guidelines. After 7.8 years of intensive treatment, the study 
group achieved lower systolic and diastolic blood pressures, 
lower HbA (1c), lower fasting serum total and low‑density 
lipoprotein cholesterol, lower fasting serum triglycerides, and 
lower 24‑ hour urine albumin excretion. As a percentage of total 
energy, fat intake was less and carbohydrate intake was more. 
This resulted in significant reduction in microvascular events 
including diabetic retinopathy by about 50%.55
The inference
A multifactorial approach, targeting control of hyperglycemia, 
blood pressure, and dyslipidemia will reduces the risk of onset 
and progression of DR.
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Other approaches to systemic medication
Anti‑platelet agents
These have been the first to be tried for DR with no proven 
efficacy. Aspirin, ticlopidine, and dipyridamole have been 
tried.57,58
PKC inhibitors
Activation of Protein kinase C has been shown to have a role to 
play in development and progression of diabetic retinopathy. 
Ruboxistaurin – a selective PKC inhibitor has been tried for DR 
as well as DME.59‑61 Although the study revealed some beneficial 
affect in moderate and severe diabetic retinopathy, the drug 
has not been approved by the USA‑FDA pending further trials.
Suppression of GLUT1
GLUT1 transports glucose between blood and the retina. 
Inhibiting the same by intra‑ocular injection of siRNAs that inhibit 
the mRNA (that codes for GLUT) has been shown to reduce 
the retinal glucose levels.62 Forskolin (which binds to GLUT1) 
when administered systemically has been shown to reduce retinal 
glucose levels in mice. Hence, GLUT1 can be a potential target 
for medical treatment‑ both locally and systemically.
Minocycline
A novel connection between bone marrow neuropathy, 
inflammation, and DR has been proposed.63 Bone marrow 
neuropathy is supposed to increase the synthesis of inflammatory 
cells. This induces a sort of systemic inflammation that affects 
hypothalamus among other organs, and adversely affects the 
microvascular and macrovascular events. Minocycline (100 mgs 
twice a day)‑ a well‑tolerated anti‑inflammatory agent has been 
shown to have some benefit in improving visual acuity in type 2 
diabetics with morbid obesity. In a pilot study of five patients 
with DME, Cukras et al. have found significant reduction in 
central macular thickness and improvement in vision.64
Rosiglitazone
As alluded to above, PPAR‑ γ agonist Rosiglitazone is primarily 
used for better control of diabetes. 65 Shen et al. have shown a 
59% reduction in progression to proliferative DR from severe 
non‑proliferative DR (47.4% vs 19.2%) with use of this drug 
over a 3‑year period. 66 However, DME has been reported as a 
complication of use of this drug as well as with Pioglitazone.67‑69 
However, Tatti et al. did not find any increased incidence of DME 
in patients being treated with Rosiglitazone.70
Celecoxib
Celecoxib is a Cyclo‑oxygenase‑2 (COX‑2) inhibitor. Since 
COX‑2 has been shown to upregulated in DR, inhibiting 
the same was thought to have benefit in DR. However, a 
placebo‑controlled trial of Oral Celecoxib (200 mgs twice a day) 
has failed show any beneficial effect on the DME. Some decrease 
in fluorescein leakage was noticed.71
Adenosine receptor agonists or adenosine reuptake inhibitors
Adenosine has been shown to have anti‑inflammatory affect. 
However, systemic administration of adenosine has severe side 
effects of hypotension, bradycardia, and sedation. Hence, agents 
that can inhibit its uptake or which mimic its action could be 
potential drugs for treatment of DR. This approach is at a 
concept level.72
Other agents that are under trial are canakinumab, a human 
anti–interleukin β monoclonal antibody (administered 
subcutaneously), Darapladib – a selective lipoprotein‑associated 
phospholipase A2 inhibitor (administered orally) and 
Darbepoetin alpha (recombinant erythropoietin).
CONCLUSIONS
The present day treatment of established diabetic retinopathy 
mainly involves laser photocoagulation, which is basically a 
destructive treatment. Preventing the onset of DR or delaying the 
progression of DR can go a long way in preserving good vision 
and avoiding the laser photocoagulation. Normalizing the blood 
glucose levels, rigid control of blood pressure, reduction in LDL 
cholesterol by use of statins, use of fenofibrates and blockade 
of renin angiotensin system have all shown some benefit in the 
occurrence or progression of DR. The concept of multifactorial 
approach to simultaneously target each of the important issues 
that face a diabetic seem to be important since the cumulative 
benefit is very significant. The challenge is in implementing 
the study regimens in the general population so as to extract 
maximum mileage from the studies, in terms of reduction in 
societal burden of visual impairment caused by diabetes.
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